SCHEMBL3011350

SCHEMBL3011350

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4F)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 2/20 0.39
HTR2A P28223 3/20 0.37
TP53 P04637 2/20 0.37
GPR119 Q8TDV5 1/20 0.37
SCN9A Q15858 1/20 0.36
LMNA P02545 2/20 0.35
CTSS P25774 3/20 0.35
MAPT P10636 3/20 0.35
CNR2 P34972 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KAT6A Q92794 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NAAA Q02083 1/20 0.34
CCR5 P51681 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020009 0.92 CTSS (0.45) TP53SCN9ALMNACTSSMAPT
SCHEMBL3011732 0.91 GPR6 (0.42) GPR6HTR2ATP53SCN9ALMNA
SCHEMBL3009935 0.91 MAPT (0.35) HTR2ATP53LMNACTSSMAPT
SCHEMBL3015637 0.90 LMNA (0.38) GPR6HTR2AGPR119LMNACTSS
SCHEMBL3014144 0.89 LMNA (0.39) GPR6HTR2AGPR119LMNACTSS
SCHEMBL3006571 0.89 GPR6 (0.39) GPR6HTR2ATP53LMNACTSS
SCHEMBL3017393 0.88 TP53 (0.43) GPR6HTR2ATP53LMNAMAPT
SCHEMBL3010789 0.87 HTR2A (0.42) GPR6HTR2ATP53SCN9ALMNA
SCHEMBL3010780 0.87 NAAA (0.41) GPR6HTR2ALMNACTSSMAPT
SCHEMBL3014963 0.86 GPR6 (0.40) GPR6HTR2ATP53LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GPR6 4245/4885HTR2A 752/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.